Increasing knowledge of the cancer glycome and the need for new options to overcome resistance to immune checkpoint inhibitors are leading to an expansion of glycoimmunology. Stanford University professor Carolyn Bertozzi demonstrated that cell-surface glycans may be tagged to become targetable glyco-immune checkpoints.
Palleon and Henlius to co-develop Bifunctional HER2-Sialidase and a second bifunctional sialidase to be jointly designed - Henlius received exclusive license for two products in China (including Hong Kong, Macau, and Taiwan); Palleon retains all other global rights - Palleon receives upfront payment and is eligible for up to $196.5 million in milestone payments - SHANGHAI, June 28, 2022 /PRNewswire/ Palleon Pharmaceuticals Inc., a companypioneering the field of glyco-immunology to treat cancer and inflammatory diseases, todayannounced a strategic collaboration with Shanghai Henlius Biotech, Inc. (2696.HK) to develop andcommercialize two bifunctional sialidase programs from Palleon's EAGLE (Enzyme-AntibodyGlyco-Ligand Editing) immuno-oncology platform, including Palleon's Bifunctional HER2-Sialidasenow in preclinical development and a second bifunctional sialidase to be developed with aproprietary target provided by Henlius. Palleon's EAGLE platform potentiates antitumor im